NCT06313398View on ClinicalTrials.gov

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

May 1, 2029

Study Completion Date

June 15, 2029

Conditions
Sickle Cell DiseaseThalassemiaHemoglobinopathy
Interventions
BIOLOGICAL

Biotin-labeled red blood cells

Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

Sponsors
All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH